Your session is about to expire
← Back to Search
Ruxolitinib for Graft-versus-Host Disease
Study Summary
This trial is researching whether a drug called ruxolitinib can help treat acute and chronic graft versus host disease.
- Graft-versus-Host Disease
- Solid Organ Transplant
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 149 Patients • NCT02038036Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Children under the age of 12 who have received a transplant of stem cells or an organ from another person are excluded.You have symptoms that resemble a combination of acute and chronic graft-versus-host disease.Children may not be able to do breathing tests to check for lung GVHD, so we will use other criteria to diagnose it. But, even if you don't have lung problems, you can still participate in the study if you meet other requirements and receive ruxolitinib.You have been diagnosed with chronic graft-versus-host disease (GVHD), regardless of severity.You have an ongoing condition called graft-versus-host disease (GVHD) in another part of your body, and you are experiencing respiratory symptoms such as rapid breathing, increased need for oxygen, and coughing.All levels of GVHD (a complication that can occur after a stem cell transplant) are allowed.You have been taking ruxolitinib for at least three weeks to treat chronic GVHD.You can continue to use certain local treatments like steroid creams or eye drops while taking ruxolitinib. Other treatments may be allowed with approval from the study's principal investigator.
- Group 1: Arm 1: Existing patients with chronic GVHD
- Group 2: Arm 2: Acute GVHD ages 0-<12 years
- Group 3: Arm 3: New onset chronic GVHD ages 0-≤18 years
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are being recruited for participation in this clinical trial?
"Affirmative. Per the information provided on clinicaltrials.gov, this research initiative is currently recruiting participants; it was initially posted in October 2021 and last updated in March 2022, with a requirement for 28 patients from 1 centre."
Is Ruxolitinib a secure medication for individuals?
"Due to the limited clinical data available for Ruxolitinib, our team at Power estimates its safety on a scale of 1-3 as a level 1."
Are there any current openings for participants in this research?
"Affirmative. The clinicaltrials.gov listing indicates that the trial is actively recruiting; it was published on October 27th 2021 and underwent its most recent update on March 31st 2022. 28 patients must be recruited from a single site for this study to move forward as planned."
What conditions does Ruxolitinib typically serve to alleviate?
"Patients with polycythemia vera, polycythemia, or those who cannot tolerate hydroxyurea may receive therapeutic relief via Ruxolitinib."
Share this study with friends
Copy Link
Messenger